Novel polypeptides with zearalenone degradation activity
By developing variant peptides with zearalenone degradation activity and their encoded polynucleotides, the problem of zearalenone inactivation in the gastric acid environment was solved, and efficient ZEN degradation was achieved.
Patent Information
- Application Number
- CN202580026830.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-23
- Filing Date
- 2025-02-24
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are unable to effectively degrade zearalenone (ZEN) and maintain its activity in the acidic environment of the stomach, leading to its inactivation in the intestines and making it impossible to effectively detoxify.
We developed variant peptides with zearalenone-degrading activity and their encoded polynucleotides, which enabled the degradation of ZEN by expression in host cells and contact with ZEN.
The variant peptides exhibit improved acid stability, maintaining activity in the acidic environment of the stomach and effectively degrading zearalenone.
Smart Images

Figure CN123125326A_ABST
Abstract
Description
Technical Field
[0001] This disclosure relates to variant peptides having zearalenone degradation activity and their uses. Background Technology
[0002] Fungal toxins are substances mainly secreted by the genera Aspergillus, Fusarium, and Penicillium, and can cause various diseases, including cancer, miscarriage, and stillbirth, when ingested by humans and livestock.
[0003] Among well-known mycotoxins, zearalenone (ZEN) is a mycotoxin produced by fungi of the genus *Fusarium*. ZEN is a nonsteroidal estrogenic mycotoxin, also known as F-2 mycotoxin or fermented estrogen substance (FES). Its chemical structure and properties are similar to the female hormone estrogen, thus causing endocrine disorders in humans and livestock. For example, a recent study reported that receptors disrupted by ZEN inhibited estrogen in mouse mammary tissue (*Ecotoxicology and Environmental Safety*, Vol. 241, August 2022, 113826). Furthermore, ZEN has been reported to stimulate the growth of human breast cancer cells with estrogen-responsive receptors (*Toxins*, 2019, 11(8), 481). Long-term ingestion of grains contaminated with zearalenone may lead to infertility in pigs, and poisoning in humans and livestock can cause cancer or mutations. Therefore, there is a need for compositions or methods that effectively degrade and detoxify zearalenone.
[0004] Meanwhile, an important consideration in the development of feed enzymes is their acid stability. This is due to the unique environment of the stomach (a digestive organ). When food enters the stomach, hydrochloric acid is secreted to turn the food into a viscous paste and control harmful bacteria. In particular, the pH in the stomach is maintained at a level of approximately 2.0 to 3.0, and if acid stability is insufficient, the enzyme will be inactivated during its passage through the stomach and become unable to function in the intestine. Therefore, the acid stability of an enzyme is important for its activity in the intestine.
[0005] Therefore, there is a need to develop an effective degrading enzyme that can effectively degrade zearalenone and is active in the intestine. Summary of the Invention
[0006] Technical issues
[0007] The object of this disclosure is to provide: a variant polypeptide having zearalenone (ZEN) degradation activity; a polynucleotide encoding the variant polypeptide; a host cell containing at least one selected from the variant polypeptide and the polynucleotide encoding the polypeptide; a composition for degrading zearalenone, comprising at least one selected from the variant polypeptide and a host cell expressing the variant polypeptide; a composition for use as a feed additive; a method for degrading zearalenone, comprising contacting zearalenone with at least one selected from the variant polypeptide and a host cell expressing the variant polypeptide; and a method for preparing a variant polypeptide having zearalenone degradation activity.
[0008] Technical solution
[0009] One object of this disclosure is to provide a variant polypeptide with zearalenone (ZEN) degradation activity.
[0010] Another objective of this disclosure is to provide a polynucleotide encoding a variant polypeptide of this disclosure.
[0011] Another object of this disclosure is to provide a host cell comprising at least one of the variant polypeptides selected from the present disclosure and a polynucleotide encoding said variant polypeptide.
[0012] Another object of this disclosure is to provide a composition for degrading ZEN, comprising at least one variant polypeptide selected from the present disclosure and a host cell containing said variant polypeptide.
[0013] Another object of this disclosure is to provide a composition for use as a feed additive, comprising at least one variant polypeptide selected from the present disclosure and a host cell containing said variant polypeptide.
[0014] Another object of this disclosure is to provide a method for degrading ZEN, which includes contacting ZEN with at least one variant polypeptide selected from the present disclosure and a host cell containing said variant polypeptide.
[0015] Another object of this disclosure is to provide a method for preparing a variant polypeptide with ZEN degradation activity, comprising: culturing a host cell containing at least one of the variant polypeptides selected from the present disclosure and a polynucleotide encoding the polypeptide; and recovering the variant polypeptide expressing ZEN degradation activity during culture.
[0016] Beneficial effects
[0017] The variant peptides disclosed herein with zearalenone (ZEN) degradation activity exhibit improved acid stability, thus enabling them to effectively degrade the mycotoxin zearalenone even under conditions of varying pH. Attached Figure Description
[0018] Figure 1 This is a schematic diagram showing the results of HPLC-UV verification of the zearalenone (ZEN) degradation activity of the variant peptides of this disclosure.
[0019] Figure 2 This is a schematic diagram showing the results of evaluating the enzymatic and acid stability of the variant peptides of this disclosure. Detailed Implementation
[0020] This disclosure will be described in detail below. Furthermore, each description and embodiment described herein can be applied to other descriptions and embodiments. That is, all combinations of the various elements disclosed herein fall within the scope of this disclosure. Moreover, the scope of this disclosure is not limited to the specific descriptions below.
[0021] Furthermore, those skilled in the art can recognize or identify many equivalents of the specific aspects of this disclosure described herein using conventional experiments. Moreover, these equivalents are intended to be included in this disclosure.
[0022] As used in this disclosure and the appended claims, the singular articles (“a,” “an,” and “the”) include plural referents unless the context clearly indicates otherwise. Furthermore, unless the context otherwise indicates, singular terms include their plural forms, and plural terms include their singular forms. As used in this disclosure and the appended claims, the term “or” may include the meaning of “and / or” unless otherwise stated.
[0023] As used herein, the term "approximately" may precede a specific numerical value. As used herein, the term "approximately" includes not only the exact numerical value specified after the term, but also a range that approximates or is close to that value. Considering the context in which the number appears, it can be determined whether the specific number mentioned is close to or approximates that number. In one instance, the term "approximately" may refer to the range of -10% to +10% of a numerical value. As another instance, the term "approximately" may refer to the range of -5% to +5% of a given numerical value. However, the term is not limited to these.
[0024] As used herein, terms such as “first, second, third…”, “i), ii), iii)…” or “(a), (b), (c), (d)…” are used to distinguish similar elements and do not imply that these elements are performed consecutively or in the listed order. For example, when these terms are used for steps of a method, purpose, or analysis, these steps may be performed simultaneously without any time interval, or at intervals of seconds, minutes, hours, days, or months.
[0025] As used herein, the term “consistently of” can mean that the unspecified component may be present, provided that the features of the matter claimed herein are substantially unaffected by the presence of the unspecified component.
[0026] As used herein, the term "composed of" means that the total percentage of a specific component is 100%. The components or features described in the term "composed of" may be necessary or mandatory. In some specific embodiments, other arbitrary or unnecessary components may be excluded in addition to those listed in the term "composed of".
[0027] As used herein, the term "comprising" means the presence of a feature, step, or component that follows the term, and does not exclude the presence or addition of at least one other feature, step, or component. As used herein, the component or feature that follows the term "comprising" may be necessary or mandatory; however, in certain specific embodiments, other optional or non-essential components or features may also be included.
[0028] As used herein, in certain specific implementations, the term "comprising" may be modified to mean "substantially consisting of" or "consisting of".
[0029] Regarding the amino acid sequences in this disclosure, even if they are disclosed as polypeptides “comprising” the amino acid sequences described by specific sequence numbers, polypeptides “composed of” the amino acid sequences described by specific sequence numbers, or polypeptides or proteins “having” the amino acid sequences described by specific sequence numbers, it is apparent that proteins having amino acid sequences in which some sequences are deleted, modified, substituted, conservedly substituted, or added may be used in this disclosure if the protein has the same or corresponding activity as the polypeptide composed of the amino acid sequences of the corresponding sequence numbers. For example, this could involve the addition of sequences that do not alter protein function, naturally occurring mutations, their silent mutations, or conserved substitutions to the N-terminus and / or C-terminus of the amino acid sequences, but is not limited thereto.
[0030] As used herein, the terms “protein” or “polypeptide” refer to a polymer or oligomer of consecutive amino acid residues. As used herein, “polypeptide,” “protein,” and “peptide” may be used interchangeably with “amino acid sequence.”
[0031] In some cases, an active amino acid sequence may be referred to as an "enzyme". In this disclosure, unless otherwise stated, amino acid sequences are described in the direction from the N-terminus to the C-terminus.
[0032] As used herein, the term "recombinant" in relation to cells, nucleic acids, peptides, or vectors means that the cell, nucleic acid, peptide, or vector has been modified by introducing a heterologous nucleic acid or peptide or by altering the native nucleic acid or peptide, or that the cell is derived from a cell that has been so modified. Thus, for example, recombinant cells can express genes not found in the natural (non-recombinant) form of the cell, or can express native genes that would otherwise be abnormally expressed, underexpressed, or not expressed at all.
[0033] As used herein, the term "isolated" refers to a substance that exists in an environment where it does not naturally exist or that does not naturally exist. It includes at least substantially the isolation of a substance (e.g., a sequence, enzyme, or nucleic acid) from a naturally associated substance found in nature (e.g., at least one other component having that substance (sequence, enzyme, or nucleic acid)).
[0034] For example, the isolated sequences, enzymes, or nucleic acids provided herein may be provided in a form that is substantially free of one or more contaminants.
[0035] Examples of the isolated substance may include: i) any substance that is not naturally occurring; ii) any substance (e.g., enzyme, variant, nucleic acid, protein, peptide, or cofactor) in which one or more or all of the naturally occurring components associated with it in nature have been removed; iii) any substance that has been artificially modified from a substance found in nature; or iv) a substance that has been modified (e.g., by increasing the copy number of a gene encoding a particular substance; by modifying a promoter naturally linked to the gene encoding a particular substance into a highly active promoter, etc.) to alter the amount of that substance relative to other related components in nature, but is not limited thereto.
[0036] As used herein, the term "wild-type" refers to a naturally occurring state without artificial modification. When the term "wild-type" is used to refer to a polypeptide, it refers to a naturally occurring polypeptide that does not have an artificial mutation (substitution, insertion, deletion, etc.) at at least one amino acid position. Similarly, when the term "wild-type" is used to refer to a polynucleotide, it refers to a polynucleotide lacking an artificial modification (substitution, insertion, deletion) of at least one nucleotide. However, polynucleotides encoding wild-type polypeptides are not limited to natural polynucleotides and also include sequences encoding any wild-type polypeptide.
[0037] As used herein, the terms "parental sequence" or "backbone" refer to a reference sequence in which modifications are introduced to produce a modified polypeptide. That is, the parental sequence can be a starting sequence in which modifications, such as substitutions, additions, and / or deletions, will be introduced. The parental sequence can be naturally occurring or wild-type, or a variant in which one or more substitutions, insertions, or deletions have occurred in the natural or wild-type, or it can be a synthetically produced sequence. When the parental sequence is an amino acid sequence that exhibits activity, i.e., the amino acid sequence of an enzyme, it can be called a parent enzyme.
[0038] As used herein, the term "reference sequence" refers to the sequence used to determine the position of an amino acid in any amino acid sequence. By comparing any amino acid sequence with the reference sequence, the position of an amino acid in any sequence corresponding to a specific position in the reference sequence can be determined.
[0039] As used herein, when referring to amino acid or nucleic acid sequences, the term "fragment" refers to a portion of the parental sequence. For example, it can be a polypeptide with one or more amino acids removed from the C-terminus or N-terminus of the parental sequence.
[0040] As used herein, an enzyme “fraction” can refer to a “functional fragment.” The term “functional fragment,” also known as an active fragment, refers to a polypeptide that is part of the parent enzyme and possesses the enzymatic activity of the parent enzyme. For example, the functional fragment of an enzyme can contain the enzyme’s catalytic site.
[0041] A fragment of an enzyme may contain a portion of the full length of the parent enzyme. For example, it may contain at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or more of the amino acids and be less than 100% of the full length of the parent enzyme, but is not limited thereto.
[0042] In this disclosure, "modification" means change or alteration. It can be a change from a naturally occurring state. In one instance, an enzyme can be altered in a way that makes it different from a parental sequence or a reference sequence.
[0043] In this disclosure, the modified enzyme can be an enzyme that does not exist in nature, i.e., an enzyme that does not exist naturally.
[0044] As used herein, the term "modified" means, for example, something that has been altered from its naturally occurring state. Modified enzymes of this disclosure include enzymes that are not naturally occurring or naturally occurring variants. For example, the modified enzymes of this disclosure are modified enzymes that have not yet been found in nature. For example, the modified enzymes of this disclosure may be enzymes that do not spontaneously occur, but are not limited thereto.
[0045] As used herein, when the term “modification” is used in relation to an amino acid / nucleic acid sequence, it can include: replacing amino acid / nucleic acid residues of the parent sequence with different amino acid / nucleic acid residues in at least a portion of the amino acid sequence; deleting amino acid / nucleic acid residues (or a series of amino acid / nucleic acid residues) of the parent sequence at at least one position; inserting amino acid / nucleic acid residues (or a series of amino acid / nucleic acid residues) into the parent sequence at at least one position; truncating the N-terminal and / or C-terminal amino acid sequence or the 5' and / or 3' terminal nucleic acid sequence, and any combination thereof.
[0046] As used herein, an enzyme “variant” or “modified polypeptide” refers to a protein that has at least one amino acid different from the parent enzyme through conserved substitution and / or modification. “Variant” and “modified polypeptide” are used interchangeably. Variants or modified polypeptides may be non-natural, but are not limited to this.
[0047] The variant differs from the parent enzyme sequence through at least one modification, such as amino acid substitution, deletion, and / or insertion.
[0048] These variants can typically be identified by modifying at least one amino acid in the parent enzyme and assessing the properties of the modified protein. That is, the ability of the variant can be enhanced, unchanged, or reduced relative to the parent enzyme.
[0049] In addition, some variants may include at least one of these regions, such as the N-terminal leader sequence or the transmembrane domain, which has been removed from the variant peptide.
[0050] Other variants may include those in which a portion has been removed from the N- and / or C-terminus of the mature protein.
[0051] The terms “variant” or “variant polypeptide” can be used interchangeably with terms that include modification, modified protein, mutant, mutant protein, divertergent, and variant, as long as these terms are used to refer to mutations, without limitation.
[0052] The variants may also include the deletion or addition of amino acids that have minimal impact on the properties and secondary structure of the polypeptide. For example, the polypeptide may be conjugated to a signal (or leader) sequence at the N-terminus of a protein that is co-translated or post-translational and involved in protein transport. Furthermore, the polypeptide may be conjugated to another sequence or linker to allow for the identification, purification, or synthesis of the polypeptide.
[0053] As used herein, the term "conservative substitution" refers to the replacement of an amino acid with another amino acid having similar structure and / or chemical properties. Such amino acid substitutions typically occur based on the similarity of the residues' polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphiphilic properties.
[0054] Throughout this disclosure, the standard single-letter and three-letter codes for naturally occurring amino acids are used. Furthermore, the amino acids mentioned herein are abbreviated according to the IUPAC-IUB nomenclature as follows:
[0055] Alanine (Ala, A) and Arginine (Arg, R)
[0056] Asparagine Asn, N-aspartic acid Asp, D
[0057] Cysteine (Cys, C) and Glutamate (Glu, E)
[0058] Glutamine (Gln, Q) and glycine (Gly, G)
[0059] Histidine (His, H) and Isoleucine (Ile, I)
[0060] Leucine (Leu, L), Lysine (Lys, K)
[0061] Methionine (Met, M) and Phenylalanine (Phe, F)
[0062] Proline (Pro, P) and Serine (S)
[0063] Threonine (Thr), T; Tryptophan (Trp), W
[0064] Tyrosine (Tyr, Y) and Valine (V)
[0065] At the same time, any amino acid can be described as Xaa or X.
[0066] In addition to naturally occurring amino acids, the commonly accepted three-letter codes can also be used for other amino acids, such as 2-aminoisobutyric acid (Aib), N-methylglycine (Sar), and α-methylglutamic acid.
[0067] Amino acids are typically classified based on the similarity of their residue polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphiphilic properties. Therefore, amino acid substitutions usually occur based on the similarity of these properties.
[0068] For example, among amino acids with charged side chains (charged amino acids), positively charged (basic) amino acids include arginine, lysine, and histidine, while negatively charged (acidic) amino acids include glutamic acid and aspartic acid. Furthermore, among amino acids with uncharged side chains (uncharged amino acids), nonpolar amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline, while polar or hydrophilic amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Among nonpolar amino acids, aromatic amino acids include phenylalanine, tryptophan, and tyrosine.
[0069] As used herein, the term "gene" refers to a polynucleotide that encodes a polypeptide and polynucleotides that contain upstream and downstream regions of the coding region. In some specific embodiments, a gene may have sequences (introns) inserted between each coding region (exon).
[0070] As used herein, the terms “homology” or “identity” refer to the degree of correlation between two given amino acid sequences or nucleotide sequences, and can be expressed as a percentage. The terms “homology” and “identity” are often used interchangeably.
[0071] Sequence homology or identity of conserved polynucleotides or polypeptides can be determined using standard alignment algorithms, with default gap penalties established by the program used. Essentially, homologous or identical sequences can typically hybridize with full-length sequences, or at least about 50%, 60%, 70%, 80%, or 90% or more of the full-length sequence, under medium to high stringency conditions. Clearly, hybridization also includes hybridization with polynucleotides containing codons that reflect common codon usage or codon degeneracy within the polynucleotide.
[0072] Whether any two polynucleotide or polypeptide sequences are homologous, similar, or identical can be determined, for example, by known computer algorithms such as the “FASTA” program with default parameters (Pearson et al., (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444). Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) can be used to determine this, as in the Needleman program (version 5.0.0 or later) of the EMBOSS software package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16:276-277) (GCG package (Devereux, J. et al., Nucleic Acids Research 12:387 (1984)), which contains BLASTP, BLASTN, and FASTA (Atschul, SF et al., J MOLEC BIOL 215:403 (1990); Guideto Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and CARILLO et al. (1988) SIAM J The method described in Applied Math 48:1073 is as follows. For example, homology, similarity, or identity can be determined using BLAST or ClustalW from the National Center for Biotechnology Information (NCBI), but is not limited to these methods.
[0073] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information using, for example, a GAP computer program (such as Needleman et al. (1970), J Mol Biol. 48:443, as disclosed in Smith and Waterman, Adv. Appl. Math (1981) 2:482). In short, the GAP program can be defined as a value obtained by dividing the number of similarly aligned symbols (i.e., nucleotides or amino acids) by the total number of symbols in the shorter sequence of the two sequences. The default parameters of the GAP procedure may include: (1) a binary comparison matrix (including values of 1 for identity and 0 for non-identity) and a weighted comparison matrix (or an EDNAFULL (EMBOSS version of NCBI NUC4.4) replacement matrix as disclosed in Schwartz and Dayhoff, Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353–358 (1979) by Gribskov et al. (1986) Nucl. Acids Res. 14: 6745); (2) a penalty of 3.0 for each vacancy and an additional penalty of 0.10 for each symbol in each vacancy (or a penalty of 10 for vacancy opening and 0.5 for vacancy extension); and (3) no penalty for terminal vacancy.
[0074] Furthermore, whether any two polynucleotide or polypeptide sequences are homologous, similar, or identical can be determined by comparing the sequences in a Southern hybridization experiment under defined, stringent conditions. The defined suitable hybridization conditions are within the scope of the art and can be determined by methods well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold SpringHarbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York). However, the methods for determining homology, similarity, or identity and suitable hybridization conditions are not limited thereto.
[0075] As used herein, the term "mature polypeptide" refers to a polypeptide that lacks a signal sequence or propeptide sequence. A mature protein / polypeptide / peptide can be the functional form of a protein / polypeptide / peptide. A mature polypeptide can be the final form resulting from translation or post-translational modifications. Examples of post-translational modifications include, but are not limited to, N-terminal or C-terminal modifications, glycosylation, phosphorylation, removal of the leader sequence, etc.
[0076] As used herein, the term “nucleic acid construct” refers to a single-stranded or double-stranded nucleic acid molecule that contains at least one regulatory sequence and is either artificially synthesized, engineered in a non-natural manner to contain a specific sequence, or isolated from nature.
[0077] As used herein, the term “expression” includes, but is not limited to, any step in peptide production, such as transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0078] As used herein, the term "expression vector" refers to a linear or circular nucleic acid molecule that contains a coding sequence and an operatively linked expression regulatory sequence.
[0079] As used herein, the term "operationally linked" refers to a construction in which a regulatory sequence is appropriately positioned to initiate the expression of a coding sequence. Thus, "operationally linked" involves attaching or connecting a regulatory region, such as a promoter, terminator, signal sequence, or enhancer region, with a functional domain having known or desired activity to a target (gene or polypeptide) to regulate its expression, secretion, or function according to known or desired activity.
[0080] As used herein, the term "cDNA" refers to the DNA sequence produced by reverse transcription of a mature spliced mRNA molecule obtainable from eukaryotic or prokaryotic cells. The cDNA sequence does not contain intron sequences that can be present in the corresponding genomic DNA. The initial primary RNA transcript is the precursor of mRNA, which undergoes a series of steps (including splicing) to become mature spliced mRNA.
[0081] As used herein, the term "regulatory sequence" refers to a polynucleotide sequence essential for the expression of a coding sequence. Each regulatory sequence can be native (from the same source) or exogenous (from a different gene) to the coding sequence. Examples of regulatory sequences include leader sequences, polyadenylated sequences, propeptide sequences, promoters, signal peptide sequences, operator sequences, sequences encoding ribosome-binding domains, and sequences that regulate the termination of transcription and translation. The smallest unit of a regulatory sequence can contain a promoter as well as sequences that terminate transcription and translation.
[0082] The following terminology system is used to describe the variations provided in this disclosure.
[0083] In this disclosure, references to a specific position in an amino acid sequence may include references to the amino acid present or substituted at that position. References to an amino acid at a specific position can be described in various ways. For example, "position 022" can be disclosed as "position 22," "amino acid at position 22," and "the 22nd amino acid." Furthermore, for example, when the amino acid at position 22 is proline (P), that amino acid can be disclosed as "P22" or "Pro22."
[0084] Amino acid substitutions can be represented by describing the amino acid before the substitution, its position, and the amino acid to be substituted in sequence. Amino acids can be represented using traditional single-letter and three-letter codes. In one instance, when the amino acid proline at position 22 in a particular sequence is substituted with threonine, it can be disclosed as "P22T" or "Pro22Thr".
[0085] Any amino acid at a specific position can be designated as "X". For example, X22 refers to any amino acid at position 22. Furthermore, when a substituted amino acid is designated as X, it means that it has been replaced by an amino acid different from the one before the substitution. For example, "P22X" means that the P at position 22 has been replaced by any non-P amino acid.
[0086] Different changes can be indicated by using the symbols " / " or "," to describe several types of amino acids simultaneously. For example, the substitution of amino acid (K) at position 43 with A or C can be interchangeably disclosed as K43A / C or K43A,C. In another instance, A / T111C indicates that amino acid A or T at position 111 was substituted with C before the substitution.
[0087] Multiple mutations can be described using "+". For example, "A45C+T111C" means that the amino acid alanine at position 45 and the amino acid threonine at position 111 are each replaced by cysteine.
[0088] The deletion of an amino acid can be represented by describing the amino acid before deletion, its position, and an asterisk (*). For example, when alanine, the amino acid corresponding to position 45 in a specific sequence, is deleted, it can be represented as A45* or (Ala45*).
[0089] The insertion of an amino acid, for example, the insertion of lysine between glycine at position 8 and amino acid 9 in a specific sequence, can be represented as Gly8GlyLys or G8GK. When at least one amino acid is inserted, for example, the insertion of both lysine and valine between glycine at position 8 and amino acid 9 in a specific sequence, it can be represented as Gly8GlyLysVal or G8GKV. In this case, the position of the inserted amino acid can be indicated by the number and letter of the amino acid preceding the inserted amino acid; in the above example, the inserted lysine and valine could be numbered 8aK and 8bV.
[0090] As used herein, the term "corresponding to" refers to an amino acid residue at a position listed in a protein or peptide, or an amino acid residue that is similar to, identical to, or homologous to a listed residue in a protein or peptide. Identification of an amino acid at a corresponding position can be achieved by referring to a specific sequence to determine a particular amino acid within the sequence. As used herein, the term "corresponding region" refers to a similar or corresponding position in a related protein or reference protein.
[0091] In this disclosure, SEQ ID NO: 1 can be used as a reference sequence to determine the position of an amino acid in any amino acid sequence.
[0092] In other words, SEQ ID NO: 1 disclosed herein can be used to identify the corresponding amino acid residues in peptides exhibiting ZEN degradation activity. Unless otherwise stated in this disclosure, residues in a specific amino acid sequence are numbered relative to SEQ ID NO: 1.
[0093] For example, based on the alignment of any amino acid sequence with SEQ ID NO: 1, each amino acid residue in the sequence can be numbered with reference to the position number of the amino acid residue corresponding to SEQ ID NO: 1. For example, the sequence alignment algorithm described herein can identify the position of an amino acid or the position where it has been modified, such as by substitution, insertion, or deletion, compared to the query sequence (also known as the “reference sequence”).
[0094] For such comparisons, the Needleman-Wunsch algorithm (Needlemanh and Wunsch, 1970, J. Mol. Biol. 48: 443-453), the Needle program in the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), etc., can be used, but are not limited to these.
[0095] In addition, multiple sequence alignment can be used to identify the corresponding amino acid residues in other ZEN degrading enzymes. Examples of known multiple sequence alignment procedures in this art include multiple sequence comparison by log-expectation (MUSCLE; version 3.5 or later; Edgar, 2004, NucleicAcids Research 32: 1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, Nucleic Acids Research 30: 3059-3066; Katoh et al., 2005, Nucleic Acids Research 33: 511-518; Katoh and Toh, 2007, Bioinformatics 23: 372-374; Katoh et al., 2009, Methods in Molecular Biology 537: 39-64; Katoh and Toh, 2010, Bioinformatics). 26:1899-1900), using ClustalW (1.83 or higher; Thompson et al., 1994, Nucleic Acids Research 22: 4673-4680), EMBOSS EMMA, etc., and can use the basic parameters of each program, but are not limited to them.
[0096] Furthermore, in cases where the relationship between enzymes from the mature polypeptide branch of SEQ ID NO: 1 cannot be detected by conventional sequence-based comparison, other pairwise sequence comparison algorithms can be used (Lindahl and Elofsson, 2000, J. Mol. Biol. 295: 613-615). Higher sensitivity can be achieved in sequence-based searches by using search procedures that utilize probabilistic representations of polypeptide families (maps) to search a database. For example, the PSI-BLAST procedure can generate maps and detect distant homologs through iterative database searches (Atschul et al., 1997, Nucleic Acids Res. 25: 3389-3402). Significantly higher sensitivity can be obtained when the polypeptide family or superfamily has one or more representatives in a protein structure database. Procedures such as GenTHREADER (Jones, 1999, J. Mol. Biol. 287: 797-815; McGuffin and Jones, 2003, Bioinformatics 19: 874-881) use information from various sources, such as PSI-BLAST, secondary structure prediction, structural alignment maps, and dissolution potential, as input to neural networks that predict the structural folding of query sequences. Similarly, the method of Gough et al., 2000, J. Mol. Biol. 313: 903-919 can be used to align sequences of unknown structures with superfamily models existing in the SCOP database. These alignments can then be used to generate homology models of peptides, and the accuracy of such models can be evaluated using various tools developed for the same purpose.
[0097] For proteins with known structures, several tools and resources are available for searching and generating structure alignments. For example, the SCOP superfamily of proteins has been structurally aligned, and these alignments are accessible and downloadable. Various algorithms, such as distance alignment matrices (Holm and Sander, 1998, Proteins 33: 88-96) or combinatorial extensions (CE) (Shindyalov and Bourne, 1998, Protein Engineering 11: 739-747), can be used to align two or more protein structures, and implementations of these algorithms can also be used to query structure databases with target structures to discover potential structural homologs (Holm and Park, 2000, Bioinformatics 16: 566-567).
[0098] The above methods are illustrative examples and are not limited thereto.
[0099] The specific implementation of this disclosure will be described in more detail below.
[0100] As used in this article, "zearalenone (ZEN)" refers to a nonsteroidal estrogenic fungal toxin produced by Fusarium fungi, particularly strains such as *F. graminearum* (Gibberella zeae), *F. culmorum*, *F. cerealis*, *F. equiseti*, *F. crookwellense*, and *F. semitectum*. It is considered one of the most widely distributed fungal toxins found in grains worldwide. ZEN is also known as F-2 toxin, Fusarium toxin, and fermented estrogen (FES), and has more than 20 isomers, but trans-α-zearalenone is the most prevalent in nature found in cereals. ZEN has been reported to cause damage primarily through hormone-like effects rather than direct toxicity, and poisoning mainly manifests as hyperhormonalemia, but may also lead to cancer or mutations. For example, ZEN has been reported to cause infertility in pregnant sows in livestock farming, with reports of ovarian abnormalities, premature birth, and abortion. Feed containing ZEN at a concentration of 50 ppb is known to cause changes in the ovaries of pigs.
[0101] As used in this article, ZEN degrading enzymes refer to enzymes that have the activity of cleaving the lactone ring ester bond of zearalenone (ZEN) and catalyzing the reaction that converts ZEN to hydrolyzed ZEN (HZEN).
[0102] In this disclosure, the degradation of ZEN can be used interchangeably with the detoxification of ZEN, the inactivation of ZEN, and the purification of ZEN.
[0103] In this disclosure, ZEN degradation activity can be measured and evaluated using methods known in the art, including the embodiments described in this disclosure. In one example, ZEN degradation activity can be confirmed by detecting the amount of zearalenone residue.
[0104] As used herein, the term "parental ZEN-degrading enzyme" refers to a ZEN-degrading enzyme modified to produce variants or variant polypeptides of the present disclosure. Specifically, the parental ZEN-degrading enzyme, parental enzyme, or parental sequence may be a naturally occurring or wild-type polypeptide or a mature polypeptide thereof, and may include variants or functional fragments thereof. However, it is not limited thereto, as long as it is a polypeptide with ZEN-degrading activity and can serve as a parent of a variant.
[0105] The parental ZEN-degrading enzyme provided herein may be, but is not limited to, the polypeptide of SEQ ID NO: 1. Furthermore, the parental ZEN-degrading enzyme may be a polypeptide having at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the polypeptide of SEQ ID NO: 1, provided that it exhibits ZEN-degrading activity, and if the polypeptide has the same or equivalent activity as the polypeptide composed of the amino acid sequence of SEQ ID NO: 1, then the polypeptide may be included without limitation within the scope of parental ZEN-degrading enzymes.
[0106] The parental ZEN-degrading enzymes of the variants presented in this article are derived from the genus *Sphingomonas*.
[0107] Furthermore, the aforementioned microorganisms are examples of microorganisms from which the parental ZEN degrading enzymes provided in this article can originate, and include microorganisms derived from taxonomically homologous microorganisms, regardless of the name of the microorganism.
[0108] The aforementioned microorganisms can be obtained from known microbial depositories such as ATCC, DSMZ, CBS, NRRL, KCTC, and KCCM.
[0109] In this disclosure, sequences “derived from” a particular microorganism are not limited to naturally occurring or producible sequences in microorganisms, but also include sequences encoded by generated genes and sequences encoded by genes isolated from microorganisms containing such genes.
[0110] For example, ZEN-degrading enzymes derived from the genus Sphingomonas include not only enzymes naturally occurring in Sphingomonas with ZEN-degrading activity, but also enzymes derived from Sphingomonas, as well as enzymes produced in other host cells through genetic modifications known in the art (e.g., transformation with a sequence encoding the enzyme).
[0111] As used in this article, "variant polypeptides with ZEN degradation activity" can be variants of the parental ZEN degrading enzyme.
[0112] As used herein, the term “variant of parental ZEN degrading enzyme” or “ZEN degrading enzyme variant” refers to a protein that has an amino acid sequence different from that of the parental ZEN degrading enzyme at at least one amino acid and has ZEN degrading activity.
[0113] "Variant polypeptide with ZEN degradation activity" can be used interchangeably with "variant of parental ZEN degrading enzyme" and "ZEN degrading enzyme variant".
[0114] The variants provided herein may be variants that have ZEN degradation activity and contain modifications of at least one amino acid in the parental ZEN degrading enzyme sequence.
[0115] Furthermore, the variant may be: i) a polypeptide having at least 70% and less than 100% sequence identity with SEQ ID NO: 1; and / or ii) a polypeptide encoded by a polynucleotide having at least 70% and less than 100% sequence identity with the sequence encoding the mature polypeptide of SEQ ID NO: 1; and / or iii) a polypeptide encoded by a polynucleotide hybridizing with (a) the sequence encoding the mature polypeptide of SEQ ID NO: 1, (b) its cDNA, or (c) the full-length complementary sequence of (a) or (b) under low stringent, medium stringent, medium-high stringent, high stringent, or very high stringent conditions; and / or iv) a functional fragment of i), ii), or iii) having ZEN degradation activity, and the variant may contain at least one amino acid replaced at positions 22, 43, 45, and 111 with different amino acid substitutions.
[0116] Specifically, the variants provided herein may have ZEN degradation activity and contain a modification of at least one amino acid in the parental ZEN degrading enzyme sequence, thereby exhibiting at least one altered function or property compared to the parental ZEN degrading enzyme.
[0117] In one specific embodiment, the variants provided herein may have ZEN degradation activity and include a modification of at least one amino acid in the parental ZEN degrading enzyme sequence, thereby exhibiting at least one altered function or property compared to the parental ZEN degrading enzyme, and may have at least one conserved substitution.
[0118] The variants provided in this article are variants of the parental ZEN degrading enzyme, and may be peptides with ZEN degrading enzyme activity.
[0119] In one specific embodiment, the variants provided herein may contain modifications at at least one position of an amino acid selected from positions 22, 43, 45, and 111 corresponding to SEQ ID NO: 1.
[0120] As used herein, the position number corresponds to a position in the polypeptide SEQ ID NO: 1, and the term “corresponds” is used as described above.
[0121] In one specific embodiment, the variants provided herein may include a modification of at least one amino acid selected from the amino acids corresponding to P22, K43, A45 and T111 of SEQ ID NO: 1.
[0122] In one specific embodiment, prior to the modifications provided in this disclosure, the amino acid corresponding to position 22 of SEQ ID NO: 1 may be proline (P); the amino acid corresponding to position 43 may be lysine (K); the amino acid corresponding to position 45 may be alanine (A); and / or the amino acid corresponding to position 111 may be threonine (T).
[0123] In one specific embodiment, the variants provided in this disclosure may include substitution of P with G, V, L, I, M, F, W, S, T, C, Y, N, Q, D, E, K, R, or H, where P is the amino acid corresponding to position 22 of SEQ ID NO: 1; as an example, it may include substitution with S, T, C, Y, N, or Q; as another example, it may include substitution with S, T, N, or Q; and as yet another example, it may include substitution with T.
[0124] In one specific embodiment, the variants provided in this disclosure may include substitution of K with G, A, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, R, or H, where K is the amino acid corresponding to position 43 of SEQ ID NO: 1; as an example, it may include substitution with G, A, V, L, I, M, F, W, or P; as another example, it may include substitution with G, A, V, L, I, or M; and as yet another example, it may include substitution with A.
[0125] In one specific embodiment, the variants provided in this disclosure may include substitution of A with G, V, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, or H, where A is the amino acid corresponding to position 45 of SEQ ID NO: 1; as an example, it may include substitution with S, T, C, Y, N, or Q; as another example, it may include substitution with S, T, C, N, or Q; and as yet another example, it may include substitution with C.
[0126] In one specific embodiment, the variants provided in this disclosure may include replacing T with G, A, V, L, I, F, W, P, S, C, Y, N, Q, D, E, K, R, or H, where T is the amino acid corresponding to position 111 of SEQ ID NO: 1; as an example, it may include replacing with S, C, Y, N, or Q; as another example, it may include replacing with S, C, N, or Q; and as yet another example, it may include replacing with C.
[0127] In one specific implementation, the variants provided herein may include replacing the amino acid corresponding to position 22 of SEQ ID NO: 1 with a polar or hydrophilic amino acid.
[0128] In one specific implementation, the variant provided herein may comprise replacing the amino acid corresponding to position 43 of SEQ ID NO: 1 with a nonpolar amino acid.
[0129] In one specific implementation, the variants provided herein may include replacing the amino acid corresponding to position 45 of SEQ ID NO: 1 with a polar or hydrophilic amino acid.
[0130] In one specific implementation, the variants provided herein may include replacing the amino acid corresponding to position 111 of SEQ ID NO: 1 with a polar or hydrophilic amino acid.
[0131] In one specific embodiment, the variants provided herein may include at least one substitution selected from P22T, K43A, A45C, and T111C of SEQ ID NO: 1. In another specific embodiment, the variants provided herein may include a combination of one, two, three, or four amino acid substitutions selected from the above-described amino acid substitutions.
[0132] In one implementation, the variants provided herein include all possible combinations of the above variants.
[0133] For example, the variant may contain amino acid modifications at positions selected from i) to xv), as a combination of the above modifications: i) position 22; ii) position 43; iii) position 45; iv) position 111; v) position 22 + position 43; vi) position 22 + position 45; vii) position 22 + position 111; viiii) position 43 + position 45; ix) position 43 + position 111; x) position 45 + position 111; xi) position 22 + position 43 + position 45; xii) position 22 + position 43 + position 111; xiii) position 22 + position 45 + position 111; xiv) position 43 + position 45 + position 111; and xv) position 22 + position 43 + position 45 + position 111.
[0134] In another instance, the variant may be a variant comprising, but not limited to, at least one of the following substitutions: i) threonine replacing the amino acid at position 22; ii) alanine replacing the amino acid at position 43; iii) cysteine replacing the amino acid at position 45; and iv) cysteine replacing the amino acid at position 111.
[0135] In another instance, the variant may include at least one modification selected from, but is not limited to:
[0136] P22T
[0137] K43A
[0138] A45C
[0139] T111C
[0140] P22T+K43A
[0141] P22T+A45C
[0142] P22T+T111C
[0143] K43A+A45C
[0144] K43A+T111C
[0145] A45C+T111C
[0146] P22T+K43A+A45C
[0147] P22T+K43A+T111C
[0148] P22T+A45C+T111C
[0149] K43A+A45C+T111C
[0150] P22T+K43A+A45C+T111C
[0151] In one embodiment, the variants provided in this disclosure may have at least about 60%, for example, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, and less than 100% sequence identity with the parental ZEN degrading enzyme; its mature polypeptide; or a functional fragment thereof.
[0152] In one embodiment, the variants provided in this disclosure may be variants having at least about 60%, for example at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, and less than 100% sequence identity with SEQ ID NO: 1.
[0153] In one embodiment, the variant provided in this disclosure may be a polypeptide encoded by a polynucleotide having at least about 60%, for example, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, and less than 100%, sequence identity with the mature polypeptide encoding SEQ ID NO: 1.
[0154] In one embodiment, the variants provided in this disclosure may be variants having at least about 60%, for example at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, and less than 100% sequence identity with the functional fragment of SEQ ID NO: 1.
[0155] Specifically, in this disclosure, a variant of SEQ ID NO: 1 containing A45C and T111C substitutions may be represented by SEQ ID NO: 5, a variant of SEQ ID NO: 1 containing K43A substitutions may be represented by SEQ ID NO: 6, and a variant of SEQ ID NO: 1 containing P22T substitutions may be represented by SEQ ID NO: 7.
[0156] Furthermore, variant polypeptides that differ from any of the listed sequences in at least one amino acid through conserved substitution and / or modification, but retain the function or properties of the protein, also fall within the scope of the polypeptides provided in this disclosure. Such modifications may include, for example, modifications that remove a portion from the N-terminus and / or C-terminus of a mature protein.
[0157] The polypeptides disclosed herein may have, for example, at least one conserved substitution while retaining at least one biological activity of any of the polypeptides in SEQ ID NO: 5 to 7. Typically, the conserved substitution has little or no effect on the activity of the produced polypeptide. Generally, the conserved substitution has little or no effect on the activity of the protein or polypeptide.
[0158] In one embodiment, the polypeptide provided in this disclosure may comprise: a polypeptide consisting of any amino acid sequence of SEQ ID NO: 5 to 7 or having at least 80%, for example, at least 85%, 90%, 95%, 97%, or 99% or higher homology or identity with any of SEQ ID NO: 5 to 7; a polypeptide comprising the above-mentioned amino acid sequences; or a polypeptide substantially composed of the above-mentioned amino acid sequences. Furthermore, polypeptides having the above-mentioned homology or identity and possessing ZEN degradation activity fall within the scope of ZEN-degrading polypeptides provided in this disclosure.
[0159] Compared to other parental ZEN degrading enzymes (such as wild-type ZEN degrading enzymes, parental ZEN degrading enzymes, and other variant peptides with ZEN degrading activity), the variant peptides provided herein may exhibit at least one selectable or detectable change in a property or attribute of the peptide.
[0160] These properties or attributes include oxidative stability, substrate specificity, catalytic activity, thermal stability, acid stability, base stability, pH activity profile, resistance to protein hydrolysis and degradation, Km, k cat k cat / Km ratio, protein folding, immune response induction, ability to bind ligands, ability to bind receptors, ability to secrete, ability to be displayed on the cell surface, ability to oligomerize, ability to send signals, ability to stimulate cell proliferation, ability to inhibit cell proliferation, ability to induce apoptosis, ability to be modified by phosphorylation or glycosylation, and / or ability to treat diseases, etc., but not limited to these.
[0161] Specifically, the variants presented in this paper may have pH stability or exhibit activities with increased pH stability compared to the parental sequence.
[0162] Enzyme stability refers to the retention of enzyme activity during storage or reaction time. To measure this change in stability, the initial enzyme activity can be measured and compared under specified conditions at time zero (100%) and after a certain time (x%). Therefore, it can represent the level of enzyme activity loss or enzyme stability. Factors affecting enzyme activity include, for example, pH, heat, and the presence of other substances (e.g., oxidants, chelating agents).
[0163] As used herein, the term "pH stability" refers to the ability of a protein to function within a specific pH range. In one embodiment, the variants provided herein may be active at about pH 2.0 to about pH 12.0, but are not limited thereto.
[0164] If a protein maintains its function within a specific pH range, it can be defined as having "pH stability," and depending on the pH range, it can be defined as having "acid resistance (acid stability)," "alkali resistance," etc.
[0165] Compared to other enzymes (e.g., wild-type enzymes, parental enzymes, and / or other variants), the increased stability includes maintaining high enzyme activity and increasing the pH range within which the protein maintains its function.
[0166] In one specific embodiment, a variant polypeptide wherein the amino acid sequence of SEQ ID NO: 1 is replaced with cysteine corresponding to amino acids 45 and 111 of SEQ ID NO: 1, a variant polypeptide wherein the amino acid sequence of SEQ ID NO: 1 is replaced with alanine, or a variant polypeptide wherein the amino acid sequence of SEQ ID NO: 1 is replaced with threonine may have acid resistance or may have enhanced acid resistance (acid stability) compared to the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.
[0167] Specifically, regarding acid resistance, the degradation rate at acidic pH can be at least 50%, specifically at least 60%, more specifically 60% to 90%, but is not limited to, relative to the degradation rate at the optimal pH. The optimal pH can be the optimal pH of the parental sequence or variant, and specifically can be pH 8. The acidic pH can be pH 2 to 4, and specifically can be pH 3.
[0168] In one specific embodiment, a variant polypeptide consisting of any of the amino acid sequences in SEQ ID NO: 5 to 7 may have acid resistance or enhanced acid resistance (acid stability) compared to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.
[0169] In one example of this disclosure, as a result of evaluating the acid resistance (acid stability) of the variant peptide, it was confirmed that the variant peptide is acid-resistant compared to the peptide of SEQ ID NO: 1, and exhibits excellent ZEN degradation activity under acidic conditions, thus confirming that the acid resistance (acid stability) has been improved.
[0170] Another aspect of this disclosure provides a polynucleotide encoding a variant polypeptide of the disclosed present invention having ZEN degradation activity.
[0171] As used herein, the term "polynucleotide" is a polymer in which nucleotide monomers are covalently linked together to form a long chain of nucleotides, and is a DNA or RNA chain of a certain length or longer. More specifically, it refers to a polynucleotide segment encoding the aforementioned variant.
[0172] The polynucleotide encoding variants of this disclosure may contain the coding sequence of the aforementioned variants. Taking into account codon degeneracy or preferred codons in the organism expressing the polypeptide, the polynucleotide may undergo various modifications in the coding region without altering the amino acid sequence of the polypeptide.
[0173] Furthermore, the polynucleotides disclosed herein may include, but are not limited to, probes prepared from known gene sequences, for example, any polynucleotide sequence that hybridizes under stringent conditions with all or part of the complementary sequence of the nucleotide sequence to encode a variant of the present disclosure.
[0174] The term "strict conditions" refers to conditions that enable specific hybridization between polynucleotides. These conditions are specifically disclosed in the literature (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989; FMAusubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York).
[0175] For example, the stringent conditions may include polynucleotides with high homology or identity, i.e., polynucleotides with at least 40%, specifically at least 90%, more specifically at least 95%, at least 96%, at least 97%, or at least 98%, or even more specifically at least 99% homology or identity, hybridizing with each other, while polynucleotides with homology or identity lower than the above-mentioned homology or identity will not hybridize with each other; or may include ordinary washing conditions for Southern hybridization, i.e., washing once, specifically twice, or three times at salt concentrations and temperatures corresponding to 60°C, 1×SSC, 0.1% SDS, specifically 60°C, 0.1×SSC, 0.1% SDS, and more specifically 68°C, 0.1×SSC, 0.1% SDS.
[0176] Hybridization requires two nucleic acids to have complementary sequences, although base mismatches are permitted due to the strictness of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in the case of DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the polynucleotides of this disclosure may also include isolated nucleic acid fragments complementary to the whole sequence as well as nucleic acid sequences substantially similar to them.
[0177] Specifically, polynucleotides exhibiting homology or identity can be detected using hybridization conditions, which include a T55°C process. m The value and the above-mentioned conditions for hybridization. Furthermore, the T... m The value can be 60°C, 63°C or 65°C, but is not limited to these, and can be appropriately adjusted by those skilled in the art for their purposes.
[0178] The appropriate stringency of hybrid polynucleotides depends on the length and complementarity of the polynucleotides, and the variables are well known in the relevant technical fields (see J. Sambrook et al., above, 9.50-9.51, 11.7-11.8).
[0179] For example, "high stringency" occurs below probe T. m Temperatures of approximately 5°C to 10°C; "medium strictness" occurs below probe T. m Temperatures of approximately 10°C to 20°C; and "low stringency" can occur in T m The temperature is approximately 20°C to 25°C, but not limited to this.
[0180] In one example, “low stringency conditions” could be pre-hybridization and hybridization at 42°C for 12 to 24 hours in 5X SSPE, 0.3% SDS, cleaved and denatured salmon sperm DNA (200 μg / mL), and 25% formamide, according to the Southern blotting standard procedure for probes at least 100 nucleotides in length. The vector material can then be washed 2 to 3 times at 50°C for 15 minutes each time with 2X SSC and 0.1% to 0.2% SDS.
[0181] In one example, “medium-tight conditions” can be pre-hybridized and hybridized at 42°C for 12 to 24 hours in 5X SSPE, 0.3% SDS, cleaved and denatured salmon sperm DNA (200 μg / mL), and 35% formamide, according to the Southern blotting standard procedure for probes at least 100 nucleotides in length. The vector material can then be washed 2 to 3 times at 55°C for 15 minutes each time with 2X SSC and 0.1% to 0.2% SDS. In another example, “medium-high-tight conditions” can be pre-hybridized and hybridized at 42°C for 12 to 24 hours in 5X SSPE, 0.3% SDS, cleaved and denatured salmon sperm DNA (200 μg / mL), and 35% formamide, according to the Southern blotting standard procedure for probes at least 100 nucleotides in length. The vector material can then be washed 2 to 3 times at 60°C for 15 minutes each time with 1 to 2X SSC and 0.1% to 0.2% SDS.
[0182] In one example, “highly stringent conditions” could be pre-hybridization and hybridization at 42°C for 12 to 24 hours in 5X SSPE, 0.3% SDS, cleaved and denatured salmon sperm DNA (200 μg / mL), and 35% formamide, according to the Southern blotting standard procedure for probes at least 100 nucleotides in length. The vector material can then be washed 2 to 3 times at 65°C for 15 minutes each time with 2X SSC and 0.1% to 0.2% SDS.
[0183] The polynucleotide encoding the variant polypeptide with ZEN-degrading activity disclosed herein may comprise any polynucleotide without limitation, as long as it encodes a polypeptide of any one of SEQ ID NO: 5 to 7 and a polypeptide with the corresponding activity. For example, the polynucleotide encoding the polypeptide with ZEN-degrading activity disclosed herein may be an amino acid sequence encoding any one of SEQ ID NO: 5 to 7 or a polynucleotide sequence of a polypeptide having at least 80% homology or identity with it.
[0184] In one embodiment, the polynucleotide encoding the variant polypeptide having ZEN degradation activity disclosed herein may consist of, but is not limited to, a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher homology or identity with any of the sequences in SEQ ID NO: 8 to 10.
[0185] The nucleic acid constructs provided herein comprise polynucleotides encoding variants of the present disclosure, said polynucleotides being operatively linked to at least one regulatory sequence that directs the expression of the coding sequence in a suitable host cell under conditions suitable for said regulatory sequence.
[0186] Polynucleotides can be manipulated in various ways to enable the expression of variants. Depending on the expression vector, manipulation of the polynucleotide may be required or necessary before insertion into the vector. Such manipulation can be performed using methods known in the art.
[0187] As used herein, the term "transformation" refers to the introduction of a vector containing a polynucleotide encoding a target protein into a host cell, so that the protein encoded by the polynucleotide can be expressed within the host cell. The transformed polynucleotide may be located within the host cell's chromosome or exist extrachromosomally, provided it can be expressed within the host cell. Furthermore, the polynucleotide contains DNA and RNA encoding the target protein. The polynucleotide can be introduced in any form, as long as it can be introduced into and expressed in the host cell. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a gene construct containing all the elements necessary for self-expression. The expression cassette may contain a promoter, transcription termination signal, ribosome binding site, and translation termination signal operatively linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. Furthermore, the polynucleotide may be introduced into the host cell as is and operatively linked to sequences necessary for expression in the host cell, but is not limited thereto.
[0188] Methods for transforming the vectors of this disclosure include any method of introducing nucleic acids into cells and can be performed by selecting appropriate standard techniques known in the art, depending on the host cell. For example, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) methods, DEAE-dextran methods, cationic liposome methods, lithium acetate-DMSO methods, etc., can be used, but the methods are not limited thereto.
[0189] As used herein, "vector" refers to a DNA product containing a base sequence encoding a polynucleotide of the variant, operatively linked to a suitable expression control region (or expression control sequence) to enable expression of the variant in a suitable host. The expression control sequence may include a promoter capable of initiating transcription, any operon sequence for regulating transcription, a sequence encoding a suitable mRNA ribosome binding site, and a termination sequence for regulating transcription and translation. Once transformed into a suitable host cell, the vector may replicate or function independently of the host genome, or it may integrate into the host genome.
[0190] There are no particular limitations on the vectors that can be used in this disclosure, and any vector known in the art may be used. Examples of commonly used vectors include plasmids, granules, viruses, and phages in their native or recombinant states. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, Charon21A, etc., can be used as phage vectors or granule vectors; and those vectors based on pBR, pUC, pBluescriptII, pGEM, pTZ, pCL, pET, etc., can be used as plasmid vectors. Specifically, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC, etc., may be used.
[0191] In one instance, a polynucleotide encoding a variant provided herein can be inserted into a chromosome via a vector for chromosomal insertion in a cell. The polynucleotide can be inserted into the chromosome via homologous recombination using any method known in the art, but is not limited thereto. A selection marker may also be included to confirm chromosomal insertion. This selection marker is used to screen vector-transformed cells, i.e., to confirm the insertion of the desired nucleic acid molecule; it may use markers that confer selectable phenotypes such as drug resistance, nutritional requirements, resistance to cytotoxic agents, or expression of surface peptides. In an environment treated with a selection agent, only cells expressing the selection marker survive or exhibit a different phenotype, thereby enabling the selection of transformed cells.
[0192] The host cell of this disclosure may contain any cell without limitation, as long as it is capable of expressing a variant of this disclosure.
[0193] The host cell disclosed herein may contain the above-described variants, polynucleotides encoding the variants, nucleic acid constructs containing the polynucleotides, and / or vectors.
[0194] The nucleic acid construct or vector can be integrated into the chromosome as described above, or maintained as a self-replicating extrachromosomal vector.
[0195] The host cell disclosed herein includes any offspring of a parent cell that is different from the parent cell due to mutations that occur during replication.
[0196] The host cell can be any cell used for recombinant production of the variant, such as a prokaryotic or eukaryotic cell.
[0197] The prokaryotic host cell can be any Gram-positive or Gram-negative bacterium.
[0198] The Gram-positive bacteria include, but are not limited to, Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, and Streptomyces.
[0199] The Gram-negative bacteria include, but are not limited to, Campylobacter, Escherichia coli, Flavobacterium, Fusobacterium, Helicobacter, Illiobacter, Neisseria, Pseudomonas, Salmonella, Vibrio (e.g., Vibrionatriegens), and Ureaplasma.
[0200] In one embodiment, the bacterial host cell may be a host cell of the genus Bacillus, and specifically, it includes Bacillus alcalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, and Bacillus subtilis. Bacillus subtilis and Bacillus thuringiensis, but not limited to these.
[0201] In one embodiment, the bacterial host cell may be a host cell of the genus Streptococcus, and specifically, it includes, but is not limited to, Streptococcus equisimilis, Streptococcus pyogenes, Streptococcus uberis, and Streptococcus equi subsp. zooepidemicus.
[0202] In one embodiment, the bacterial host cell may be a host cell of the genus Streptomyces, and specifically, it includes, but is not limited to, *Streptomyces achromogenes*, *Streptomyces avermitilis*, *Streptomyces coelicolor*, *Streptomyces griseus*, and *Streptomyces lividans*.
[0203] In one embodiment, the bacterial host cell can be a host cell of the genus *Corynebacterium*, and can be *Corynebacterium glutamicum*, *Corynebacterium crudilactis*, *Corynebacterium deserti*, *Corynebacterium efficiens*, *Corynebacterium callunae*, *Corynebacterium stationis*, *Corynebacterium singulare*, *Corynebacterium halotolerans*, *Corynebacterium striatum*, *Corynebacterium ammoniagenes*, *Corynebacterium pollutisoli*, *Corynebacterium imitans*, or *Corynebacterium stomatologicum*. It includes, but is not limited to, *testudinoris* or *Corynebacterium flavescens*.
[0204] The host cell can be a eukaryotic cell, such as a mammalian, insect, plant, or fungal cell.
[0205] The host cell may be a fungal cell. In this disclosure, "fungus" includes Ascomycota, Basidiomycota, Chytridiomycota, Zygomycota, Oomycota, and all imperfect fungi.
[0206] The host cell for fungi can be a yeast cell. In this disclosure, "yeast" includes yeasts that produce ascospores (Endomycetales), yeasts that produce basidiospores, and yeasts belonging to the class Deuteromycetes (Blastomycetes). However, this classification may vary and can be defined as described in Biology and Activities of Yeast (Skinner, Passmore, and Davenport, editors, Soc. App. Bacteriol. Seminar Series No. 9, 1980).
[0207] Yeast host cells can be cells from genera such as *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Komagatella*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia*, for example, *Kluyveromyces lactis*, *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norvensis*, *Saccharomyces orbensis*, *Saccharomyces oviformis*, and *Komagatella*. phaffii) or Yarrowia lipolytica cells.
[0208] The host cell of the fungus can be a filamentous fungal cell. "Filamentous fungi" encompasses all filamentous forms within the kingdom Mycophylum and the subphylum Oomycota (as defined in the literature (Hawksworth et al., 1995)). Filamentous fungi are typically characterized by hyphal walls composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth occurs through hyphal elongation, and carbon metabolism is strictly aerobic. In contrast, yeasts, such as Saccharomyces cerevisiae, exhibit vegetative growth through the germination of single-celled cells, and carbon metabolism can be fermentative.
[0209] Filamentous fungal host cells include *Acremonium*, *Aspergillus*, *Aureobasidium*, *Bjerkandera*, *Ceriporiopsis*, *Chrysosporium*, *Coprinus*, *Coriolus*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, and *Neurospora*. Cells of the genera *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Phanerochaete*, *Phlebia*, *Piromyces*, *Pleurotus*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, *Trametes*, or *Trichoderma*.
[0210] For example, the filamentous fungal host cells may include *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus fumigatus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Bjerkandera adusta*, *Ceriporiopsisaneirina*, *Ceriporiopsis caregiea*, *Ceriporiopsis gilvescens*, *Ceriporiopsis pannocinta*, *Ceriporiopsis rivulosa*, and *Ceriporiopsis rubiginosa*. subrufa, Ceriporiopsis subvermispora, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Coprinus cinereus, Coriolus hirsutus, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium scabra culmorum), Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, FusariumFusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola insolens, Humicola lanuginosa, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium purpurogenum, Phanerochaete chrysosporium, Phlebia radiata, Pleurotus eryngii The fungi include *Trichoderma eryngii*, *Thielavia terrestris*, *Trametes villosa*, *Trametes versicolor*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride*. However, they are not limited to these.
[0211] In one instance of this disclosure, Escherichia coli is used as a host cell, but is not limited thereto.
[0212] The host cell expressing the variant polypeptide of this disclosure may be a host cell containing at least one selected from the variant polypeptide of this disclosure, a polynucleotide encoding the polypeptide, and a vector containing the polynucleotide.
[0213] Another aspect of this disclosure provides a composition comprising at least one selected from variant polypeptides of this disclosure, a polynucleotide encoding the polypeptide, a vector containing the polynucleotide, and a host cell expressing the polypeptide.
[0214] The compositions disclosed herein can be used to convert the substrate of ZEN-degrading enzymes into the final product, and can be compositions for degrading ZEN, compositions for detoxifying ZEN present in food and / or feed, or compositions used as feed additives, but are not limited thereto.
[0215] The variant polypeptides disclosed herein, the polynucleotides encoding the polypeptides, the vectors containing the polynucleotides, and / or the host cells expressing the polypeptides can be used to degrade zearalenone.
[0216] The terminology used in this article is as described above, and the degradation of ZEN can be used to refer to the detoxification of ZEN, the inactivation of ZEN, and the purification of ZEN-induced contamination.
[0217] In one implementation, ZEN can be present in food.
[0218] In one implementation, ZEN can be present in animal feed.
[0219] In one embodiment, ZEN present in food and / or feed can be degraded and detoxified using the compositions disclosed herein.
[0220] In addition to the variations provided herein, the compositions of this disclosure may also contain other components. Those skilled in the art can appropriately select the components to be added to the compositions of this disclosure.
[0221] In one specific embodiment, the compositions disclosed herein may also contain any component suitable for converting the substrate of the ZEN degrading enzyme into the final product.
[0222] Examples of substances that can be added include, but are not limited to, stabilizers, surfactants, detergent builders, chelating agents, dispersants, enzymes, enzyme stabilizers, catalysts, activators, carriers, binders, lubricants, disintegrants, excipients, solubilizers, suspending agents, colorants, flavorings, buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, diluents, lubricants, and preservatives.
[0223] In one embodiment, in addition to the variations provided herein, the compositions provided herein may also contain naturally occurring or non-naturally occurring substances.
[0224] In one embodiment, in addition to the variations provided herein, the compositions provided herein may also contain additional enzymes for ZEN degradation.
[0225] In one implementation, the vector can be integrated into the chromosome as described above, or maintained as a self-replicating extrachromosomal vector.
[0226] In the compositions disclosed herein, the variant polypeptide can be recovered from the microorganism expressing the polypeptide, or the host cell expressing the polypeptide can itself be used as a source of the polypeptide without recovering the polypeptide.
[0227] Another aspect of this disclosure provides a method for degrading zearalenone, comprising contacting zearalenone with at least one selected from variant polypeptides of this disclosure, a polynucleotide encoding the polypeptide, a vector containing the polynucleotide, and a host cell expressing the polypeptide.
[0228] The terminology used in this article is as described above.
[0229] In the methods disclosed herein, the variant polypeptide can be recovered from the microorganism expressing the polypeptide, or the host cell expressing the polypeptide can itself be used as a source of the polypeptide without recovering the polypeptide.
[0230] Methods for producing variants of this disclosure may include: culturing host cells; and recovering variants expressed during the culturing process.
[0231] As used herein, the term "culture" refers to the growth of host cells under appropriately controlled environmental conditions. The culture process of this disclosure can be carried out in suitable culture media and under suitable culture conditions known in the art. Those skilled in the art can readily adapt and use this culture process depending on the selected strain. Specifically, the culture can be a batch culture, a continuous culture, or a fed-batch culture, but is not limited thereto.
[0232] As used herein, the term "culture medium" refers to a mixture containing nutrients as the main components for culturing host cells, and the culture medium provides nutrients, growth factors, etc., and contains water, which is essential for survival and development. Specifically, any culture medium and culture conditions can be used to culture host cells without particular limitation, as long as the culture medium is used for the general culture of host cells. The host cells can be cultured under aerobic conditions in a general culture medium containing suitable carbon sources, nitrogen sources, phosphorus sources, inorganic compounds, amino acids and / or vitamins, while controlling temperature, pH, etc.
[0233] In this disclosure, the carbon source comprises carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, and maltose; sugar alcohols such as mannitol and sorbitol; organic acids such as pyruvic acid, lactic acid, and citric acid; or amino acids such as glutamic acid, methionine, and lysine. Additionally, natural organic nutrients such as starch hydrolysate, molasses, brown molasses, rice bran, cassava, bagasse, and corn steep liquor can be used. Specifically, carbohydrates such as glucose and sterilized pre-treated molasses (i.e., molasses converted to reducing sugars) can be used, and various other carbon sources can be used without limitation in appropriate amounts. These carbon sources can be used alone or in combination of at least two, but are not limited thereto.
[0234] As nitrogen sources, inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, and ammonium nitrate can be used, or organic nitrogen sources such as amino acids (e.g., glutamate, methionine, and glutamine), peptone, NZ-amines, meat extracts, yeast extracts, malt extracts, corn steep liquor, casein hydrolysate, fish or its decomposition products, and defatted soybean meal or its degradation products can be used. These nitrogen sources can be used alone or in combination of at least two, but are not limited to this.
[0235] Potassium dihydrogen phosphate, dipotassium hydrogen phosphate, or their corresponding sodium-containing salts can be used as phosphorus sources. As for inorganic compounds, sodium chloride, calcium chloride, ferric chloride, magnesium sulfate, ferric sulfate, manganese sulfate, calcium carbonate, etc., can be used. Furthermore, amino acids, vitamins, and / or suitable precursors can be included. These components or precursors can be added to the culture medium in batches or continuously. However, the culture medium is not limited to these.
[0236] During the culture of the host cells, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid may be added to the culture medium in an appropriate manner to adjust the pH of the medium. During culture, antifoaming agents such as polyethylene glycol esters of fatty acids may be used to suppress foaming. To maintain an aerobic state in the culture medium, oxygen or oxygen-containing gas may be injected. To maintain an anaerobic or slightly aerobic state in the culture medium, gases, including nitrogen, hydrogen, or carbon dioxide, must not be injected. However, the culture conditions are not limited to these.
[0237] The temperature during the cultivation period of this disclosure can range from 20°C to 55°C, specifically from 25°C to 40°C, but is not limited thereto. Cultivation can continue until the desired amount of useful material is obtained, specifically from 24 hours to 196 hours, but is not limited thereto.
[0238] In one specific implementation, the variant expressed during culture can be recovered using methods known in the art to which this disclosure pertains. For example, the variant can be recovered from the nutrient medium using conventional processes, including but not limited to collection, centrifugation, filtration, extraction, spray drying, evaporation, or precipitation.
[0239] The recovery method may be to collect the desired variant using suitable methods known in the art, depending on the method of culturing the host cells of this disclosure, such as batch, continuous, or fed-batch culture. For example, the variant can be recovered from the culture medium or host cells using suitable methods known in the art, such as centrifugation, filtration, crystallization, treatment with a protein precipitant (salting out), extraction, ultrasonic disruption, ultrafiltration, dialysis, various types of chromatography (such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, and affinity chromatography), HPLC, and combinations thereof.
[0240] In another specific implementation, variants expressed by the host cells during culture may not be recovered. In the above specific implementation, the host cells expressing the variants can be used as a source of the variants.
[0241] Another aspect of this disclosure provides the use of the variant polypeptides of this disclosure as ZEN-degrading enzymes.
[0242] The terminology used in this article is as described above.
[0243] Another aspect of this disclosure provides the use of a composition comprising at least one of the variant polypeptides selected from the present disclosure and a host cell comprising said variant polypeptide for the degradation of ZEN.
[0244] The terminology used in this article is as described above.
[0245] Mode of implementing the present invention
[0246] This disclosure will be described in detail below with reference to specific embodiments. Furthermore, each description and embodiment described herein can be applied to other descriptions and embodiments. That is, all combinations of the various elements disclosed herein fall within the scope of this disclosure. Moreover, the scope of this disclosure is not limited to the specific descriptions below.
[0247] Furthermore, those skilled in the art can recognize or identify many equivalents of the specific aspects of this disclosure described herein using conventional experiments. Moreover, these equivalents are intended to be included in this disclosure.
[0248] Example 1. Preparation of expression vectors for ZEN-degrading enzyme ZOR_7 and its variants
[0249] Example 1-1. Preparation of expression vector for ZEN-degrading enzyme ZOR_7
[0250] The polynucleotide (SEQ ID NO: 2) encoding an α / β hydrolase (hereinafter referred to as ZOR_7; SEQ ID NO: 1) derived from the genus Sphingomonas was synthesized by Cosmo Genetech and cloned into the pET vector (Novagen). Using this as a template, the hydrolase sequence, its polynucleotide sequence, and the primer sequences used are shown in Tables 1 and 2 below.
[0251] [Table 1]
[0252]
[0253] [Table 2]
[0254]
[0255] Specifically, ZOR_7 was prepared using a synthetic gene construct, primers (SEQ ID Nos. 3 and 4 in Table 2), and a PCR premix (iNtRON, Cat. No. 25185). PCR was performed using an Eppendorf Mastercycler Nexus GX2 under the following conditions.
[0256] Initial denaturation – 94℃, 2 minutes
[0257] Transformation – 94℃, 20 seconds
[0258] Annealing – 55℃, 10 seconds
[0259] Extend – 72℃, 2 minutes (denaturation to extension cycle 25 times).
[0260] Final extension – 72℃, 5 minutes
[0261] The resulting PCR product and vector were treated with restriction enzymes (NcoI and NotI), ligated with T4 DNA ligase (NEB, Cat# M0202S), transformed into E. coli DH5α, and sequence mutations were confirmed by sequencing.
[0262] Examples 1-2. Preparation of expression vectors for ZEN-degrading enzyme ZOR_7 variant
[0263] Mutation sites were selected to improve the acid stability of the ZEN degrading enzyme ZOR_7, and primers were designed to prepare three variants with point mutations or multiple mutations (hereinafter referred to as ZOR7_M1, ZOR7_M2, and ZOR7_M3; SEQ ID NO: 5, 6, and 7). The sequence mutation position refers to the mutation position based on the sequence of SEQ ID NO: 1, and the amino acid sequence of the variant, its polynucleotide sequence, and the primer sequences used to prepare the variant are listed in Tables 3 and 4 below.
[0264] [Table 3]
[0265]
[0266]
[0267]
[0268]
[0269] [Table 4]
[0270]
[0271] Specifically, three ZOR_7 variants were prepared by PCR using the templates, primers (SEQ ID NOs: 11 to 18 in Table 4) and PCR premix (iNtRON, Cat. No. 25185) constructed in Examples 1-1. PCR was performed using an Eppendorf Mastercycler Nexus GX2 under the following reaction conditions.
[0272] Initial denaturation – 94℃, 2 minutes
[0273] Transformation – 94℃, 20 seconds
[0274] Annealing – 55℃, 10 seconds
[0275] Extend – 72℃, 2 minutes (denaturation to extension cycle 25 times).
[0276] Final extension – 72℃, 5 minutes
[0277] The truncated variants generated were ligated using the QuickChange site-directed mutagenesis kit (Agilent, Cat# 200518) and then transformed into E. coli DH5α strains to confirm the sequence mutations by sequencing.
[0278] Example 2. Expression and purification of ZEN-degrading enzyme ZOR_7 and its variants
[0279] The ZOR_7 and three variant vectors prepared in Example 1 were transformed into *E. coli* BL21 (DE3), inoculated into sterile LB medium (BD Difco), and pre-cultured at 37°C and 200 rpm for 16 hours. Subsequently, 1 / 100 of the culture volume was inoculated into flasks containing sterile LB medium and cultured at 37°C and 200 rpm until OD (dose elapsed). 600The concentration was 0.4 to 0.5. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was then added to a final concentration of 1 mM, and the cells were cultured for 16 hours before centrifugation to recover them. The recovered cells were added to and resuspended in 20 mL of lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM imidazole), and the crude enzyme solution was obtained by sonication and centrifugation. The crude enzyme solution was slowly poured into Ni-NTA resin (Qiagen, Cat. No. 30230) for adsorption, then washed with washing buffer (same as lysis buffer except for 20 mM imidazole) and eluted with elution buffer (same as lysis buffer except for 250 mM imidazole) to purify the enzyme. The purified enzyme solution was placed in an Amicon Ultra-15 centrifuge filter (UFC901024, Merck) and concentrated by centrifugation at 4°C, 4,000 rpm for 20 minutes. Subsequently, 50 mM Tris-HCl pH 7.4 buffer was added to the concentrate, and buffer exchange was performed by repeated centrifugation 2 to 3 times. The final concentrate was then used as an enzyme solution.
[0280] Protein concentration was determined by mixing 5 μL of diluted enzyme solution with 250 μL of Bradford solution (Quick Start™ Bradford 1x staining reagent, #5000205) and measuring the absorbance at 595 nm.
[0281] Example 3. Evaluation of the activity of ZEN-degrading enzyme ZOR_7 and its variants
[0282] Example 3-1. Evaluation of ZEN degradation activity of ZOR_7 and its variants
[0283] To analyze the activity of ZOR_7 and its three variants against zearalenone (ZEN) prepared in Example 2, zearalenone (CAS 17924-92-4) was dissolved in acetonitrile to prepare an enzyme solution. The reaction was carried out at pH 8 and 37°C for 4 minutes, and the reaction was terminated by treatment with methanol. The residual amount of ZEN in the reaction mixture was measured using HPLC-UV (High Performance Liquid Chromatography-Ultraviolet), and the degradation activity of the enzyme was calculated using the ratio of total ZEN degradation. The HPLC-UV analytical conditions are as follows.
[0284] As a result, when comparing relative activities based on ZOR_7 activity, all three variants showed a slight increase in ZEN degradation activity (Table 5 and...). Figure 1 ).
[0285] [Table 5]
[0286]
[0287] Example 3-2. Evaluation of the acid stability of ZOR_7 and its variants
[0288] To evaluate the acid stability of ZOR_7 and the three variants prepared in Example 2, 2.5 μL of glycine-HCl (1 M, pH 3.0) was mixed with 47.5 μL of purified enzyme solution and acid-treated at 37°C for 60 min. Subsequently, each mixture was subjected to ZEN degradation under the same reaction conditions as in Example 3-1, except for pH. The amount of ZEN degraded at pH 3 relative to the amount degraded at pH 8 is shown in the figure. Figure 2 middle.
[0289] Relative activity (%) is calculated by dividing the amount of ZEN degraded at pH 3 by the amount of ZEN degraded at pH 8.
[0290] As an evaluation of residual enzyme activity, it was confirmed that M1, M2, and M3 all showed at least a 20% improvement in residual activity compared to ZOR_7. Figure 2 ).
[0291] The results above confirm that the three variants of the ZEN degrading enzyme ZOR_7 (ZOR7_M1 of SEQ ID NO: 5, ZOR7_M2 of SEQ ID NO: 6, and ZOR7_M3 of SEQ ID NO: 7) exhibit improved acid stability compared to the ZEN degrading enzyme of SEQ ID NO: 1.
[0292] As described above, those skilled in the art will understand that this disclosure may be implemented in other specific forms without departing from the technical spirit or essential characteristics of this disclosure. Therefore, the above embodiments should be interpreted as exemplary, not as limiting the disclosure. It should be understood that all variations or modifications derived from the definitions and scope of the claims and their equivalents fall within the scope of this disclosure.
Claims
1. A variant polypeptide with zearalenone (ZEN) degradation activity, wherein: i) The variant polypeptide has at least 70% and less than 100% sequence identity with SEQ ID NO: 1; and / or ii) The variant polypeptide is a polypeptide encoded by a polynucleotide that has at least 99% and less than 100% sequence identity with the mature polypeptide encoding SEQ ID NO: 1; and / or iii) The variant polypeptide is a polypeptide encoded by a polynucleotide that hybridizes under low-strict, medium-strict, medium-high-strict, high-strict, or very high-strict conditions with (a) the coding sequence of the mature polypeptide of SEQ ID NO:1, (b) its cDNA, or (c) the full-length complementary sequence of (a) or (b); and / or iv) The variant polypeptide is a functional fragment of polypeptide i), ii), or iii) that has zearalenone (ZEN) degradation activity; and The variant polypeptide contains any modification selected from the group consisting of: The amino acid at at least one position selected from positions 22, 43, 45, and 111 is replaced with a different amino acid. The position number corresponds to the position in the polypeptide of SEQ ID NO:
1.
2. The variant polypeptide according to claim 1, wherein, Prior to modification with the variant polypeptide exhibiting zearalenone (ZEN) degradation activity, the amino acid at position 22 is proline (P); the amino acid at position 43 is lysine (K); the amino acid at position 45 is alanine (A); and the amino acid at position 111 is threonine (T).
3. The variant polypeptide of claim 1, wherein the variant polypeptide comprises an amino acid substitution at a position selected from i) to iii): i) The 45th and 111th positions; ii) The 43rd position; and iii) 22nd position The position number corresponds to the position in the polypeptide of SEQ ID NO:
1.
4. The variant polypeptide of claim 1, wherein the variant polypeptide comprises at least one substitution selected from i) to iii): i) Replace the amino acid at position 45 and the amino acid at position 111 with cysteine; ii) Replace the amino acid at position 43 with alanine; and iii) Replace the amino acid at position 22 with threonine. The position number corresponds to the position in the polypeptide of SEQ ID NO:
1.
5. The variant polypeptide of claim 1, wherein the variant polypeptide has increased pH stability compared to the polypeptide consisting of the amino acid sequence of SEQ ID NO:
1.
6. A polynucleotide encoding a variant polypeptide according to any one of claims 1 to 5.
7. A host cell comprising at least one of a variant polypeptide selected from any one of claims 1 to 5 and a polynucleotide encoding said variant polypeptide.
8. A composition for degrading zearalenone, comprising at least one variant polypeptide selected from any one of claims 1 to 5 and a host cell expressing said variant polypeptide.
9. A composition for use as a feed additive, comprising at least one variant polypeptide selected from any one of claims 1 to 5 and a host cell expressing said variant polypeptide.
10. A method for degrading zearalenone, comprising contacting zearalenone with at least one variant polypeptide selected from any one of claims 1 to 5 and a host cell expressing said variant polypeptide.
11. A method for producing a variant peptide with ZEN degradation activity, comprising: Culture host cells comprising at least one of the variant polypeptides selected from any one of claims 1 to 5 and a polynucleotide encoding said variant polypeptide; and The variant peptides expressed during culture that have ZEN degradation activity were recovered.
